CDK4/6 Inhibitor Plus Camrelizumab for PD-1 Inhibitor Refractory R/M NPC

Sponsor
Sun Yat-sen University
Study ID
NCT05724355
Phase
PHASE2
Status
Unknown

Conditions

  • Nasopharyngeal Carcinoma

Eligibility Criteria

Sex
ALL
Age
18 Years - 70 Years
Healthy Volunteers
Not accepted

Interventions

Study Details

Because most patients with R/M NPC have received long-term maintenance of immunotherapy at the time of initial treatment and the first-line treatment, there are a large number of PD-1 inhibitor refractory patients. How to deal with the ICIs resistance is an urgent problem in clinical practice.

Key Dates

Start date
Sep 1, 2022
Status verified
Feb 2023
Primary completion
Oct 31, 2023
Completion
Oct 31, 2024

Study Design

Enrollment
32 participants (estimated)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: Dalpiciclib plus Camrelizumab

Primary Outcome Measure

Objective response rate (ORR) [ Time Frame: 1 year ]

Central Contacts

Related Studies